Cargando…
Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
OBJECTIVE: We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. METHODS: The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first po...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996600/ https://www.ncbi.nlm.nih.gov/pubmed/29889028 http://dx.doi.org/10.4274/mirt.70783 |
_version_ | 1783330902975184896 |
---|---|
author | Vural Topuz, Özge Görtan, Fatma Arzu Kaya Döner, Zübeyde Rana Önsel, Çetin Sayman, Haluk Burçak |
author_facet | Vural Topuz, Özge Görtan, Fatma Arzu Kaya Döner, Zübeyde Rana Önsel, Çetin Sayman, Haluk Burçak |
author_sort | Vural Topuz, Özge |
collection | PubMed |
description | OBJECTIVE: We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. METHODS: The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. RESULTS: Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p<0.001) than that in patients with positive SLNBs. CONCLUSION: Our results showed that (18)F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame. |
format | Online Article Text |
id | pubmed-5996600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59966002018-06-14 Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels Vural Topuz, Özge Görtan, Fatma Arzu Kaya Döner, Zübeyde Rana Önsel, Çetin Sayman, Haluk Burçak Mol Imaging Radionucl Ther Original Article OBJECTIVE: We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. METHODS: The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. RESULTS: Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p<0.001) than that in patients with positive SLNBs. CONCLUSION: Our results showed that (18)F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame. Galenos Publishing 2018-06 2018-06-07 /pmc/articles/PMC5996600/ /pubmed/29889028 http://dx.doi.org/10.4274/mirt.70783 Text en ©Copyright 2018 by Turkish Society of Nuclear Medicine / Molecular Imaging and Radionuclide Therapy published by Galenos Yayinevi. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Vural Topuz, Özge Görtan, Fatma Arzu Kaya Döner, Zübeyde Rana Önsel, Çetin Sayman, Haluk Burçak Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels |
title | Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels |
title_full | Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels |
title_fullStr | Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels |
title_full_unstemmed | Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels |
title_short | Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels |
title_sort | usefulness of (18)f-fdg pet/ct in cutaneous melanoma patients with negative sentinel lymph nodes and high clark levels |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996600/ https://www.ncbi.nlm.nih.gov/pubmed/29889028 http://dx.doi.org/10.4274/mirt.70783 |
work_keys_str_mv | AT vuraltopuzozge usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels AT gortanfatmaarzu usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels AT kayadonerzubeyderana usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels AT onselcetin usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels AT saymanhalukburcak usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels |